Literature DB >> 9853427

Prognostic significance of proliferative activity, DNA-ploidy, p53 and Ki-ras point mutations in colorectal liver metastases.

A Russo1, M Migliavacca, V Bazan, N Maturi, V Morello, G Dardanoni, G Modica, P Bazan, I Albanese, M La Farina, R M Tomasino.   

Abstract

Paired colorectal liver metastases (CLM) and normal tissue samples from a consecutive series of 36 patients were studied prospectively. MIB-1 expression was studied by immunohistochemistry on paraffin-embedded sections. DNA ploidy and S-phase fraction (SPF) measurements were performed by flow cytometry on frozen tissues. Mutations within the p53 (exons 5-8) and c-Ki-ras (codons 12 and 13) genes were detected by PCR single-strand conformation polymorphism analysis followed by sequencing. A high correlation was observed between the MIB-1 LI and SPF value (rho=0.81; P<0.01). Moreover, p53 gene mutations were associated with either high MIB-1 LI and high SPF. In univariate analysis, SPF and MIB-1 levels were related to risk of death. The association between overall survival and DNA-ploidy or p53 mutations did not reach statistical significance, but a slightly better survival was observed for patients either with DNA-diploid tumours or without mutations (P=0.05 and P=0.06, respectively). SPF was shown by multivariate Cox model analysis to be an independent prognostic variable and thus it might be a useful prognostic factor in patients with CLM.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9853427      PMCID: PMC6496582     

Source DB:  PubMed          Journal:  Cell Prolif        ISSN: 0960-7722            Impact factor:   6.831


  40 in total

1.  Modalities of synthesis of Ki67 antigen during the stimulation of lymphocytes.

Authors:  F Lopez; F Belloc; F Lacombe; P Dumain; J Reiffers; P Bernard; M R Boisseau
Journal:  Cytometry       Date:  1991

Review 2.  Colorectal cell kinetics.

Authors:  R Gilliland; K E Williamson; R H Wilson; N H Anderson; P W Hamilton
Journal:  Br J Surg       Date:  1996-06       Impact factor: 6.939

3.  Nuclear distribution of the Ki-67 antigen during the cell cycle: comparison with growth fraction in human breast cancer cells.

Authors:  J H van Dierendonck; R Keijzer; C J van de Velde; C J Cornelisse
Journal:  Cancer Res       Date:  1989-06-01       Impact factor: 12.701

4.  Mutations in the p53 gene occur in diverse human tumour types.

Authors:  J M Nigro; S J Baker; A C Preisinger; J M Jessup; R Hostetter; K Cleary; S H Bigner; N Davidson; S Baylin; P Devilee
Journal:  Nature       Date:  1989-12-07       Impact factor: 49.962

5.  A study of stabilisation of p53 protein versus point mutation in colorectal carcinoma.

Authors:  K J Cripps; C A Purdie; P J Carder; S White; K Komine; C C Bird; A H Wyllie
Journal:  Oncogene       Date:  1994-09       Impact factor: 9.867

6.  Patterns of DNA-ploidy in operable colorectal carcinoma: a prospective study of 100 cases.

Authors:  A Russo; V Bazan; S Plaja; P Leonardi; P Bazan
Journal:  J Surg Oncol       Date:  1991-09       Impact factor: 3.454

7.  p53 point mutation and survival in colorectal cancer patients.

Authors:  H S Goh; J Yao; D R Smith
Journal:  Cancer Res       Date:  1995-11-15       Impact factor: 12.701

8.  The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins.

Authors:  C Schlüter; M Duchrow; C Wohlenberg; M H Becker; G Key; H D Flad; J Gerdes
Journal:  J Cell Biol       Date:  1993-11       Impact factor: 10.539

9.  Mathematical analysis of DNA distributions derived from flow microfluorometry.

Authors:  P N Dean; J H Jett
Journal:  J Cell Biol       Date:  1974-02       Impact factor: 10.539

10.  Cell kinetics of hepatic metastases as a prognostic marker in patients with advanced colorectal carcinoma.

Authors:  R Silvestrini; A Costa; L Gennari; R Doci; E Bombardieri; L Bombelli
Journal:  HPB Surg       Date:  1990-04
View more
  6 in total

Review 1.  Surgery for colorectal liver metastases: The evolution of determining prognosis.

Authors:  Gaya Spolverato; Aslam Ejaz; Nilo Azad; Timothy M Pawlik
Journal:  World J Gastrointest Oncol       Date:  2013-12-15

2.  Management of colorectal cancer patients after resection of liver metastases: can we offer a tailored treatment?

Authors:  Miriam López-Gómez; Paloma Cejas; María Merino; David Fernández-Luengas; Enrique Casado; Jaime Feliu
Journal:  Clin Transl Oncol       Date:  2012-08-22       Impact factor: 3.405

3.  Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases.

Authors:  Georgios Karagkounis; Michael S Torbenson; Hubert D Daniel; Nilofer S Azad; Luis A Diaz; Ross C Donehower; Kenzo Hirose; Nita Ahuja; Timothy M Pawlik; Michael A Choti
Journal:  Cancer       Date:  2013-09-19       Impact factor: 6.860

4.  KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer.

Authors:  S Renaud; B Romain; P-E Falcoz; A Olland; N Santelmo; C Brigand; S Rohr; D Guenot; G Massard
Journal:  Br J Cancer       Date:  2015-02-17       Impact factor: 7.640

5.  Stage IV colon cancer patients without DENND2D expression benefit more from neoadjuvant chemotherapy.

Authors:  Wen-Juan Ma; Yukun Chen; Jian-Hong Peng; Chaoming Tang; Ling Zhang; Min Liu; Shanshan Hu; Haineng Xu; Hua Tan; Yangkui Gu; Zhi-Zhong Pan; Gong Chen; Zhong-Guo Zhou; Rong-Xin Zhang
Journal:  Cell Death Dis       Date:  2022-05-06       Impact factor: 9.685

Review 6.  The Shifting Paradigm of Prognostic Factors of Colorectal Liver Metastases: From Tumor-Centered to Host Immune-Centered Factors.

Authors:  Matteo Donadon; Ana Lleo; Luca Di Tommaso; Cristiana Soldani; Barbara Franceschini; Massimo Roncalli; Guido Torzilli
Journal:  Front Oncol       Date:  2018-05-28       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.